Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

CEO

Mr. Stephan Jackman

Employees

Country

United States

ISIN

US02262M6057

Listings

0 Comments

Share your thoughts

FAQ

What is Alzamend Neuro stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Alzamend Neuro stocks are traded under the ticker 9ZT0.STU.

When is the next Alzamend Neuro earnings date?▼

Alzamend Neuro is going to release the next earnings report on July 01, 2026.

What were Alzamend Neuro earnings last quarter?▼

9ZT0.STU earnings for the last quarter are -0.5 EUR per share, whereas the estimation was -0.46 EUR resulting in a -9.43% surprise. The estimated earnings for the next quarter are N/A EUR per share.

How many employees does Alzamend Neuro have?▼

As of May 25, 2026, the company has 4 employees.

In which sector is Alzamend Neuro located?▼

Alzamend Neuro operates in the Health & Wellness sector.

When did Alzamend Neuro complete a stock split?▼

The last stock split for Alzamend Neuro was on May 12, 2025 with a ratio of 1:9.

Where is Alzamend Neuro headquartered?▼

Alzamend Neuro is headquartered in Atlanta, United States.